Literature DB >> 10648862

Rapid cloning of HLA class I cDNAs by locus specific PCR.

D R Johnson1, B C Biedermann, B Mook-Kanamori.   

Abstract

The human major histocompatibility complex (MHC) class I loci, human leukocyte antigen (HLA)-A, -B, -C, encode highly polymorphic molecules that mediate immune recognition of infectious pathogens and can initiate the rapid rejection of transplanted tissue. Cloning of HLA class I alleles is complicated by polymorphism as well as interlocus homology. Here, HLA class I cDNAs are amplified by PCR using one common primer with one of three locus specific primers whose 3' ends map to conserved, locus specific nucleotides. Using these primers, HLA-A, -B, and -C alleles were cloned from a number of cell lines and two different HLA-B alleles were cloned from a single, heterozygous cell line. The amplified products encode the entire extracellular portion of the class I molecules. An amplified HLA-A allele was cloned into an expression vector and the protein product was detected on the surface of a transfected cell. A premature termination codon was engineered into the HLA-A allele by site directed mutagenesis and the soluble protein product was detected in the culture medium of transfected cells. Therefore, these primers can be used to rapidly clone, alter, and express HLA class I molecules. This method may expedite the generation of reagents for testing the antigen specificity of antibodies, natural killer cells, or T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648862     DOI: 10.1016/s0022-1759(99)00121-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome.

Authors:  Alessandro Didonna; Noriko Isobe; Stacy J Caillier; Kathy H Li; Alma L Burlingame; Stephen L Hauser; Sergio E Baranzini; Nikolaos A Patsopoulos; Jorge R Oksenberg
Journal:  Hum Mol Genet       Date:  2015-10-03       Impact factor: 6.150

2.  MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.

Authors:  Ruth L Vinall; Alexandra Z Ripoll; Sisi Wang; Chong-Xian Pan; Ralph W deVere White
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

3.  Differential MHC class I expression in distinct leukocyte subsets.

Authors:  Justin M Greene; Roger W Wiseman; Simon M Lank; Benjamin N Bimber; Julie A Karl; Benjamin J Burwitz; Jennifer J Lhost; Oriana E Hawkins; Kevin J Kunstman; Karl W Broman; Steven M Wolinsky; William H Hildebrand; David H O'Connor
Journal:  BMC Immunol       Date:  2011-07-15       Impact factor: 3.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.